PMID- 33530463
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210228
IS  - 2075-4426 (Print)
IS  - 2075-4426 (Electronic)
IS  - 2075-4426 (Linking)
VI  - 11
IP  - 2
DP  - 2021 Jan 26
TI  - Pharmacogenomics of Allopurinol and Sulfamethoxazole/Trimethoprim: Case Series 
      and Review of the Literature.
LID - 10.3390/jpm11020071 [doi]
LID - 71
AB  - Severe cutaneous adverse drug reactions (SCAR) such as the Stevens-Johnson 
      syndrome/toxic epidermal necrolysis (SJS/TEN) and drug rash with eosinophilia and 
      systemic symptoms/drug-induced hypersensitivity syndrome (DIHS) can be induced by 
      a plethora of medications. The field of pharmacogenomics aims to prevent severe 
      adverse drug reactions by using our knowledge of the inherited or acquired 
      genetic risk of drug metabolizing enzymes, drug targets, or the human leukocyte 
      antigen (HLA) genotype. Dermatologists are experts in the diagnosis and 
      management of severe cutaneous adverse drug reactions (SCAR) in both the 
      inpatient and outpatient setting. However, most dermatologists in the US have not 
      focused on the prevention of SCAR. Therefore, this paper presents a case series 
      and review of the literature highlighting salient examples of how dermatologists 
      can apply pharmacogenomics in the diagnosis and especially in the prevention of 
      SCAR induced by allopurinol and sulfamethoxazole/trimethoprim, two commonly 
      prescribed medications.
FAU - Ikediobi, Ogechi
AU  - Ikediobi O
AD  - Department of Dermatology, University of California, San Diego, CA 92093, USA.
FAU - Schneider, Jeremy A
AU  - Schneider JA
AD  - Department of Dermatology, University of California, San Diego, CA 92093, USA.
LA  - eng
PT  - Case Reports
DEP - 20210126
PL  - Switzerland
TA  - J Pers Med
JT  - Journal of personalized medicine
JID - 101602269
PMC - PMC7911847
OTO - NOTNLM
OT  - Stevens-Johnson syndrome
OT  - dermatology
OT  - drug-induced hypersensitivity syndrome
OT  - pharmacogenomics
OT  - severe cutaneous adverse drug reaction
OT  - toxic epidermal necrolysis
COIS- The authors declare no conflict of interest.
EDAT- 2021/02/04 06:00
MHDA- 2021/02/04 06:01
PMCR- 2021/01/26
CRDT- 2021/02/03 01:01
PHST- 2021/01/05 00:00 [received]
PHST- 2021/01/22 00:00 [revised]
PHST- 2021/01/23 00:00 [accepted]
PHST- 2021/02/03 01:01 [entrez]
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2021/02/04 06:01 [medline]
PHST- 2021/01/26 00:00 [pmc-release]
AID - jpm11020071 [pii]
AID - jpm-11-00071 [pii]
AID - 10.3390/jpm11020071 [doi]
PST - epublish
SO  - J Pers Med. 2021 Jan 26;11(2):71. doi: 10.3390/jpm11020071.